阿霉素、5-氟尿嘧啶和丝裂霉素-C联合化疗对晚期结直肠癌的疗效。
Effect of adriamycin, 5-fluorouracil and mitomycin-C combination chemotherapy in advanced colorectal cancer.
作者信息
Stathopoulos G P, Stergiou G S, Golematis B, Thalassinos N, Fillipakis M
机构信息
Second University Department of Medicine, Hippokration Hospital, Athens, Greece.
出版信息
Oncology. 1995 Jul-Aug;52(4):306-9. doi: 10.1159/000227479.
One hundred and seventy-four patients with advanced colorectal cancer were treated with 5-fluorouracil (5-FU), mitomycin-C (MIT-C) and Adriamycin (ADR) (FAM). The total response rate was 26.4%. A higher response rate (37%) was observed in patients with liver metastases only, compared to other sites of metastases (p < 0.02). Complete remission were achieved only in patients with liver metastases (15%). Male patients with liver metastases had a higher response rate than females (p < 0.03). Twenty-five patients previously treated unsuccessfully with 5-FU and MIT-C showed a response rate of 28% when ADR was added to the regimen. The patients' median survival was 11 months (range: from 3 to > or = 60 months). The median survival of patients with liver metastases was 11 months and that of responders (20 months) was significantly longer than that of nonresponders (7 months; p < 0.0001). These results suggest that the FAM combination might be considered an eligible chemotherapy schedule for patients with liver metastatic disease from colorectal cancer.
174例晚期结直肠癌患者接受了5-氟尿嘧啶（5-FU）、丝裂霉素-C（MIT-C）和阿霉素（ADR）联合治疗（FAM方案）。总缓解率为26.4%。仅发生肝转移的患者缓解率较高（37%），与其他转移部位的患者相比有统计学差异（p<0.02）。仅肝转移患者实现了完全缓解（15%）。肝转移男性患者的缓解率高于女性（p<0.03）。25例先前接受5-FU和MIT-C治疗无效的患者，在治疗方案中加入ADR后缓解率为28%。患者的中位生存期为11个月（范围：3至≥60个月）。肝转移患者的中位生存期为11个月，缓解者的中位生存期（20个月）显著长于未缓解者（7个月；p<0.0001）。这些结果表明，FAM联合方案可能被认为是结直肠癌肝转移患者合适的化疗方案。
Zotero 插件